Sangamo Therapeutics, Inc (SGMOQ) stock
SGMOQOTCBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Số liệu tài chính tới Q1 năm tài chính 2026, quý kết thúc ngày Mar 31, 2026Last filing: 10-Q on May 14, 2026Score 4/30
$0.10−0.01 (-8.17%)
Close on Oct 19, 2026Market cap $39.43MP/E –Yield –
Sangamo Therapeutics revenue
Revenue is the money a company takes in from selling its products and services, before any costs are deducted.
Sangamo Therapeutics's revenue for the twelve months ending Mar 31, 2026 was $34.56M, down 45.8% year over year. For fiscal 2025 it was $39.55M, down 31.6% from the year before. Over ten years it grew 0.0% a year on average. The highest annual figure on record is $176.23M in fiscal 2023.
Annual revenue
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $39.55M | -31.6% |
| FY2024 | Dec 31, 2024 | $57.80M | -67.2% |
| FY2023 | Dec 31, 2023 | $176.23M | +58.3% |
| FY2022 | Dec 31, 2022 | $111.30M | +0.5% |
| FY2021 | Dec 31, 2021 | $110.70M | -6.3% |
| FY2020 | Dec 31, 2020 | $118.19M | +15.4% |
| FY2019 | Dec 31, 2019 | $102.43M | +21.3% |
| FY2018 | Dec 31, 2018 | $84.45M | +131.0% |
| FY2017 | Dec 31, 2017 | $36.57M | +88.6% |
| FY2016 | Dec 31, 2016 | $19.39M | -51.0% |
| FY2015 | Dec 31, 2015 | $39.54M | -13.8% |
| FY2014 | Dec 31, 2014 | $45.87M | +90.1% |
| FY2013 | Dec 31, 2013 | $24.13M | +11.4% |
| FY2012 | Dec 31, 2012 | $21.66M | +109.9% |
| FY2011 | Dec 31, 2011 | $10.32M | -50.4% |
| FY2010 | Dec 31, 2010 | $20.81M | -6.2% |
| FY2009 | Dec 31, 2009 | $22.19M | – |
Quarterly revenue
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q1 FY2026 | Mar 31, 2026 | $1.44M | -77.6% |
| Q4 FY2025 | Dec 31, 2025 | $14.23M | +88.4% |
| Q3 FY2025 | Sep 30, 2025 | $581.00K | -98.8% |
| Q2 FY2025 | Jun 30, 2025 | $18.31M | +5042.1% |
| Q1 FY2025 | Mar 31, 2025 | $6.44M | +1238.3% |
| Q4 FY2024 | Dec 31, 2024 | $7.55M | +269.8% |
| Q3 FY2024 | Sep 30, 2024 | $49.41M | +425.8% |
| Q2 FY2024 | Jun 30, 2024 | $356.00K | -94.8% |
| Q1 FY2024 | Mar 31, 2024 | $481.00K | -99.7% |
| Q4 FY2023 | Dec 31, 2023 | $2.04M | -92.5% |
| Q3 FY2023 | Sep 30, 2023 | $9.40M | -64.5% |
| Q2 FY2023 | Jun 30, 2023 | $6.84M | -76.7% |
| Q1 FY2023 | Mar 31, 2023 | $157.96M | +459.5% |
| Q4 FY2022 | Dec 31, 2022 | $27.23M | -2.7% |
| Q3 FY2022 | Sep 30, 2022 | $26.46M | -7.4% |
| Q2 FY2022 | Jun 30, 2022 | $29.38M | +5.4% |
| Q1 FY2022 | Mar 31, 2022 | $28.23M | +7.4% |
| Q4 FY2021 | Dec 31, 2021 | $27.99M | +8.5% |
| Q3 FY2021 | Sep 30, 2021 | $28.56M | -50.6% |
| Q2 FY2021 | Jun 30, 2021 | $27.87M | +29.3% |
| Q1 FY2021 | Mar 31, 2021 | $26.28M | +101.0% |
| Q4 FY2020 | Dec 31, 2020 | $25.80M | -53.0% |
| Q3 FY2020 | Sep 30, 2020 | $57.76M | +163.1% |
| Q2 FY2020 | Jun 30, 2020 | $21.55M | +22.8% |
| Q1 FY2020 | Mar 31, 2020 | $13.08M | +62.0% |
| Q4 FY2019 | Dec 31, 2019 | $54.85M | +104.4% |
| Q3 FY2019 | Sep 30, 2019 | $21.96M | -6.8% |
| Q2 FY2019 | Jun 30, 2019 | $17.55M | -18.1% |
| Q1 FY2019 | Mar 31, 2019 | $8.07M | -36.1% |
| Q4 FY2018 | Dec 31, 2018 | $26.84M | +105.2% |
| Q3 FY2018 | Sep 30, 2018 | $23.56M | +99.5% |
| Q2 FY2018 | Jun 30, 2018 | $21.42M | +159.5% |
| Q1 FY2018 | Mar 31, 2018 | $12.64M | +269.0% |
| Q4 FY2017 | Dec 31, 2017 | $13.08M | +46.6% |
| Q3 FY2017 | Sep 30, 2017 | $11.81M | +318.4% |
| Q2 FY2017 | Jun 30, 2017 | $8.25M | +122.9% |
| Q1 FY2017 | Mar 31, 2017 | $3.43M | – |
| Q4 FY2016 | Dec 31, 2016 | $8.92M | – |
| Q3 FY2016 | Sep 30, 2016 | $2.82M | – |
| Q2 FY2016 | Jun 30, 2016 | $3.70M | – |
See a number that looks wrong?